SCHEMBL3762973

SCHEMBL3762973

O=C(CN1CCN(c2cnc(-c3ccccc3Cl)cn2)CC1)N1CCN(C2CCC2)CC1

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 2/20 0.43
CNR1 P21554 1/20 0.43
ALDH1A1 P00352 5/20 0.41
MAPT P10636 3/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
PTPN11 Q06124 1/20 0.41
PARP1 P09874 1/20 0.41
KDM4E B2RXH2 3/20 0.40
HRH3 Q9Y5N1 6/20 0.40
KDM2B Q8NHM5 2/20 0.40
HSD17B10 Q99714 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3770763 0.93 CNR2 (0.50) CNR2CNR1ALDH1A1MAPTKMT2A
SCHEMBL3766212 0.89 DPP4 (0.42) CNR2CNR1ALDH1A1MAPTKMT2A
SCHEMBL3769368 0.89 DPP4 (0.42) CNR2CNR1ALDH1A1MAPTKMT2A
SCHEMBL3763022 0.87 ALDH1A1 (0.46) ALDH1A1MAPTNPSR1PARP1KDM4E
SCHEMBL3768258 0.86 KDM4E (0.46) ALDH1A1KDM4EHRH3KDM2B
SCHEMBL3780678 0.86 KDM4E (0.39) ALDH1A1MAPTNPSR1PARP1KDM4E
SCHEMBL3769132 0.86 ALDH1A1 (0.43) ALDH1A1MAPTKMT2AMEN1SMN1; SMN2
SCHEMBL3774132 0.86 HRH3 (0.42) ALDH1A1MAPTSMN1; SMN2PARP1KDM4E
SCHEMBL3773597 0.85 HRH3 (0.43) CNR2ALDH1A1MAPTPARP1KDM4E
SCHEMBL3771213 0.85 SMN1; SMN2 (0.52) ALDH1A1MAPTKMT2AMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 CNR2 47/4885CNR1 76/4885ALDH1A1 1210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.